Scepticism over Tamiflu study findings

  Doubts have resurfaced about the efficacy of oseltamivir, despite a large new study touting a 19% mortality reduction with the drug.

An international meta-analysis involving more than 29,000 patients reports that adults hospitalised for H1N1 influenza were 19% less likely to die if they were given oseltamivir (Tamiflu) or another neuraminidase inhibitor during the 2009-2010 pandemic, irrespective of when the drug was given.

The Roche-funded study, published Wednesday in Lancet Respiratory Medicine, also found that